AVBP (ArriVent BioPharma) Net Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is ArriVent BioPharma Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. ArriVent BioPharma's Net Income for the three months ended in Dec. 2024 was $-20.63 Mil. ArriVent BioPharma's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, ArriVent BioPharma's net margin for the quarter that ended in Dec. 2024 was 0.00%.

The historical rank and industry rank for ArriVent BioPharma's Net Margin % or its related term are showing as below:

AVBP's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -131.37
* Ranked among companies with meaningful Net Margin % only.

ArriVent BioPharma Net Margin % Historical Data

The historical data trend for ArriVent BioPharma's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArriVent BioPharma Net Margin % Chart

ArriVent BioPharma Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Net Margin %

ArriVent BioPharma Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Margin %	Get a 7-Day Free Trial							-	-	-	-	-

Competitive Comparison of ArriVent BioPharma's Net Margin %

For the Biotechnology subindustry, ArriVent BioPharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ArriVent BioPharma's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ArriVent BioPharma's Net Margin % distribution charts can be found below:

* The bar in red indicates where ArriVent BioPharma's Net Margin % falls into.

Save Embed

;

Save Embed

;

ArriVent BioPharma Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

ArriVent BioPharma's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin	=	Net Income (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-80.488	/	0
	=	%

ArriVent BioPharma's Net Margin for the quarter that ended in Dec. 2024 is calculated as

Net Margin	=	Net Income (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-20.633	/	0
	=	%

ArriVent BioPharma (NAS:AVBP) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

ArriVent BioPharma Net Margin % Related Terms

Thank you for viewing the detailed overview of ArriVent BioPharma's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

ArriVent BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 Campus Boulevard, Suite 100, Newtown Square, Philadelphia, PA, USA, 19073

Website

https://www.arrivent.com

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.